Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

TCX vs MLAB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLAB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

MLAB Overall Winner 6-Pillar Tally: TCX 2 – 4 MLAB Matrix Metrics: TCX 2 – 8 MLAB

As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over Tucows, Inc (TCX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TCX carries a Unified Composite Score of 44.1/100 (HOLD) at $15.10 (30.5x Forward P/E, -4.3% operating margin), whereas MLAB carries 41.8/100 (SELL) at $134.47 (24.9x Forward P/E, 10.4% operating margin).

  • Composite vs. Pillar Nuance: While TCX currently prints a higher short-term Unified Composite Score (44.1/100 HOLD vs. MLAB 41.8/100 SELL), MLAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (10.4% vs. -4.3% operating margin) and revenue trajectory (+2.6% vs. +1.4% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TCX vs MLAB
TCX NASDAQ
Tucows, Inc
Services-Computer Processing & Data Preparation
$15.10
+31.83% 1D
Market Cap $131.2M
TTM Revenue $396M
Forward P/E 30.5x
Beta / 30D Vol 0.52β · 151% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 5.0 Fund 36.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 68
RSI-14: 67.9 · SMA20: $11.90 · SMA50: $10.69
MLAB NASDAQ Head-to-Head Winner
Mesa Laboratories Inc
Industrial Instruments For Measurement, Display, And Control
$134.47
+0.28% 1D
Market Cap $781.3M
TTM Revenue $251M
Forward P/E 24.9x
Beta / 30D Vol 1.14β · 52% Vol
Unified Composite Score
41.8 / 100 SELL
Tech 20.0 Fund 36.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.9% over 20 days), RSI 55
RSI-14: 54.7 · SMA20: $130.31 · SMA50: $129.37

6-Pillar Scorecard Institutional Category Breakdown (TCX 2 – 4 MLAB)

Columns: Metric · TCX · MLAB
1. Valuation Multiples TCX
Forward P/E 30.5x 24.9x
Trailing P/E 30.5x 119.8x
PEG Ratio 1.89x N/M
EV / Revenue 1.7x 3.1x
2. Growth & Scale MLAB
Revenue Growth (YoY) +1.4% +2.6%
Earnings Growth (YoY) +90.2% +67.0%
TTM Revenue (USD) $396M $251M
Market Cap $131.2M $781.3M
3. Profitability & Quality MLAB
Gross Margin 36.5% 64.8%
Operating Margin -4.3% 10.4%
Net Profit Margin -17.9% 2.6%
Return on Equity (ROE) -1011.6% 3.6%
4. Balance Sheet & Cash Flow MLAB
Cash Generation (TTM) -$23M $49M EBITDA
Cash Flow Margin -5.7% 19.4% EBITDA Mgn
Net Cash / Leverage $531M Net Debt $34.66 Book/Sh · 3.6% ROE
Dividend Yield None (0.00%) 0.47%
5. Options & Positioning TCX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 67.3% (7th %ile) N/A (N/A)
Put/Call OI Skew 0.23x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat MLAB
OpEx & R&D Intensity 40.8% of Rev ($162M) 54.4% of Rev ($137M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Infrastructure Operator Scientific & Technical Instruments Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TCX (2) vs MLAB (8)
Institutional Metric TCX MLAB Criterion Row Edge
Market Capitalization
Scale
$131.2M $781.3M Larger Scale MLAB
Trailing P/E Ratio
Valuation
30.5x 119.8x Lower Multiple TCX
Forward P/E Ratio
Valuation
30.5x 24.9x Lower Multiple MLAB
Revenue Growth (YoY)
Growth
+1.4% +2.6% Higher Growth MLAB
Operating Margin (TTM)
Profitability
-4.3% 10.4% Higher Margin MLAB
Net Profit Margin
Profitability
-17.9% 2.6% Higher Margin MLAB
Return on Equity (ROE)
Capital Efficiency
-1011.6% 3.6% Higher ROE MLAB
52-Week Range Position
Momentum
40% ($8–$25) 87% ($70–$144) Stronger Trend MLAB
Beta / 30D Volatility
Risk Regime
0.52β · 151% Vol 1.14β · 52% Vol Lower Realized Risk MLAB
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 41.8 / 100 (SELL) Higher Composite TCX
Trailing 12M Revenue (USD)
Operating Scale
$396M $251M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
36.5% 64.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.89x PEG · 1.7x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$23M ($531M Net Debt) $49M EBITDA ($34.66 Book/Sh · 3.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCX +52.22 pp
TCX: +61.27% · MLAB: +9.05%
3M Horizon TCX +35.24 pp
TCX: +47.56% · MLAB: +12.32%
6M Horizon MLAB +32.9 pp
TCX: +1.79% · MLAB: +34.69%
1Y Horizon MLAB +108.9 pp
TCX: -27.04% · MLAB: +81.86%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TCX vs MLAB. Trailing 12-month operating profitability (TCX -4.3% vs MLAB 10.4%) and valuation multiples (TCX 30.5x vs MLAB 24.9x Forward P/E) are benchmarked directly in Pillar 4 below.

TCX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$396M
Gross Margin36.5%
Op. Margin-4.3%
ROE / Fwd P/E-1011.6% · 30.5x
MLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$251M
Gross Margin64.8%
Op. Margin10.4%
ROE / Fwd P/E3.6% · 24.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TCX CONSOLIDATION
71d in phase · OBV DISTRIBUTION
Current IV 67.3%
IV Percentile 7th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TCX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TCX Moat Profile Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
Competes within the Software - Infrastructure value chain with $131.2M market capitalization and -4.3% operating margin.
OpEx & R&D Reinvestment 40.8% of Rev ($162M)
90D Engineering Disclosures 0 Published
MLAB Moat Profile Cyclical / Execution-Driven Positioning
Scientific & Technical Instruments Operator
Competes within the Scientific & Technical Instruments value chain with $781.3M market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($137M)
90D Engineering Disclosures 0 Published

Investor FAQ TCX vs MLAB Key Questions & Quantitative Answers

As of Nov 17, 2026, Mesa Laboratories Inc (MLAB) is the stronger overall head-to-head candidate over Tucows, Inc (TCX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). TCX carries a Unified Composite Score of 44.1/100 (HOLD) at $15.10 (30.5x Forward P/E, -4.3% operating margin), whereas MLAB carries 41.8/100 (SELL) at $134.47 (24.9x Forward P/E, 10.4% operating margin). Composite vs. Pillar Nuance: While TCX currently prints a higher short-term Unified Composite Score (44.1/100 HOLD vs. MLAB 41.8/100 SELL), MLAB captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (10.4% vs. -4.3% operating margin) and revenue trajectory (+2.6% vs. +1.4% YoY).

MLAB leads the Growth & Scale pillar: TCX posts +1.4% YoY revenue growth and +90.2% YoY earnings growth on $396M TTM revenue (36.5% gross margin, -4.3% operating margin), compared with MLAB at +2.6% YoY revenue growth and +67.0% YoY earnings growth on $251M TTM revenue (64.8% gross margin, 10.4% operating margin). On trailing 12-month operating scale, TCX generates $396M in USD-normalized revenue versus $251M for MLAB. In operating R&D and SG&A reinvestment, TCX deploys 40.8% of Rev ($162M) (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($137M) (0 disclosures) for MLAB.

TCX screens cheaper on headline valuation multiples. TCX trades at 30.5x Forward P/E, 30.5x Trailing P/E, 1.89x PEG, and 1.7x EV/Revenue (-5.7% FCF margin), whereas MLAB trades at 24.9x Forward P/E, 119.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (19.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TCX (-1011.6% ROE) versus MLAB (3.6% ROE) capital efficiency.

In options market volatility and institutional positioning, TCX carries 67.3% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.52β · 151% Vol realized risk). By comparison, MLAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.14β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.